logo-loader
viewCo-Diagnostics

Co-Diagnostics to ring Nasdaq opening bell in San Francisco

The Nasdaq invitation comes after the Utah-based company achieved several milestones in 2019

Co-Diagnostics - Co-Diagnostics Inc to ring the Nasdaq Stock Market opening bell in San Francisco
Based in Salt Lake City, the company develops and markets advanced diagnostics technology

Co-Diagnostics Inc (NASDAQ:CODX) announced Thursday it has been invited to ring the Nasdaq Stock Market opening bell in San Francisco. 

The company, which is part of the Nasdaq Biotech Index, will ring the bell on January 13. 

“2019 was a momentous year for Co-Diagnostics,” said CEO Dwight Egan in a statement. 

READ: Co-Diagnostics still a Buy on launch of in vitro diagnostic tests in India: HC Wainwright

Egan noted that the company had achieved several milestones in 2019. They include:

  • the completion and CE marking of its first multiplex diagnostic for Zika/dengue/chikungunya;
  • the launch of several multiplex tests for the mosquito abatement market, which helped the company record its first domestic revenue;
  • the expansion of a license agreement with LGC, Biosearch Technologies for Co-Diagnostics’ CoPrimer technology; and
  • the inauguration of its joint venture manufacturing facility in India, followed by the IVD approval for five diagnostic assays from the Indian equivalent of the US Food and Drug Administration. 

“We extend our gratitude to all shareholders, investors, customers, and partners for their support, and hope you will join us as we build on these milestones to make 2020 the best year yet for CODX,” he added.

Salt Lake City, Utah-based Co-Diagnostics is a molecular diagnostics company that develops and markets advanced diagnostics technology.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Co-Diagnostics

Price: 19.57 USD

NASDAQ:CODX
Market: NASDAQ
Market Cap: $537.34 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Co-Diagnostic prepares test for new strain of coronavirus in...

Co-Diagnostic (NASDAQ: CODX) CEO Dwight Egan joined Proactive’s Steve Darling from New York to discuss the company being able to prepare a test for the deadly coronavirus in just 8 days. Amazing fast for such a test. Egan discussed how they were able to do that and when the test may be...

on 5/2/20

2 min read